Savara/$SVRA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Savara

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Ticker

$SVRA
Primary listing

Industry

Biotechnology

Employees

59

ISIN

US8051111016

Savara Metrics

BasicAdvanced
$466M
-
-$0.49
0.44
-

What the Analysts think about Savara

Analyst ratings (Buy, Hold, Sell) for Savara stock.

Bulls say / Bears say

Savara's experimental therapy, molgramostim, met the primary endpoint in a late-stage trial for treating autoimmune pulmonary alveolar proteinosis (aPAP), leading to a 31% increase in share price. (reuters.com)
Analysts have set an average 12-month price target of $8.83 for Savara, indicating a potential upside of over 200% from the current stock price. (stockanalysis.com)
Piper Sandler maintained a 'Buy' rating for Savara with a price target of $7.00, reflecting confidence in the company's growth prospects. (markets.businessinsider.com)
Savara's stock reached a 52-week low of $2.60 amid market challenges, reflecting a significant downturn and investor concerns. (investing.com)
The company reported a loss of $38 million for the financial year ending December 31, 2022, highlighting ongoing profitability challenges. (finance.yahoo.com)
Analysts do not anticipate Savara will be profitable this year, raising concerns about its financial sustainability. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.

Savara Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Savara Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SVRA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs